Blockchain Registration Transaction Record

Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis

Quantum BioPharma advances LUCID-MS, a patented therapy targeting demyelination and neuroprotection in multiple sclerosis. Phase 1 trials show safety; IND submitted to FDA. Learn how this could transform MS treatment.

This news matters because multiple sclerosis affects millions worldwide, and current treatments primarily target inflammation without adequately addressing the underlying myelin damage and neurodegeneration. Quantum BioPharma’s LUCID-MS program directly targets demyelination and neuroprotection, potentially filling a critical gap in MS care. If successful, this therapy could slow disease progression, preserve mobility, and improve the quality of life for patients who currently face limited options for halting long-term disability. The completion of phase 1 studies and submission of an IND application bring this promising candidate closer to clinical trials, offering new hope for the MS community.